Home Biosimilar Antibodies Others Others Ontamalimab (Anti-MADCAM1)
For research use only. Not for use in humans.

Ontamalimab (Anti-MADCAM1)

Synonyms: MAdCAM-1,MACAM1

Ontamalimab (Anti-MADCAM1) is a fully human IgG2 monoclonal antibody targeting mucosal addressin cell adhesion molecule-1 (MAdCAM-1) with potential for the research of Crohn's disease. MW: 145.5 kD.

Ontamalimab (Anti-MADCAM1)

Quality Control

Batch: A240401 Purity: 99% Protein concentration: 6.291mg/ml Endotoxin Level: ＜1EU/mg
99

Mechanism of Action

Description
Ontamalimab (Anti-MADCAM1) is a fully human IgG2 monoclonal antibody targeting mucosal addressin cell adhesion molecule-1 (MAdCAM-1) with potential for the research of Crohn's disease. MW: 145.5 kD.

Product Details

CAS No. 2098790-40-8
Molecular Weight 145.5 kDa
Isotype Human IgG2SA
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT07052682 TERMINATED Drug: Ontamalimab Steatohepatitis Takeda 2023-01-18 PHASE1
NCT03283085 COMPLETED Drug: 25 mg Ontamalimab|Drug: 75 mg Ontamalimab Crohn's Disease; Ulcerative Colitis Shire 2018-02-27 PHASE3
NCT03290781 COMPLETED Drug: Ontamalimab Ulcerative Colitis Shire 2018-04-04 PHASE3
NCT03627091 TERMINATED Drug: Ontamalimab Crohn's Disease Shire 2019-02-06 PHASE3
NCT03566823 TERMINATED Crohn's Disease Shire 2018-07-17 PHASE3
NCT03259334 TERMINATED Drug: Ontamalimab Ulcerative Colitis Shire 2018-02-09 PHASE3

(data from https://clinicaltrials.gov, updated on 2025-08-19)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.